Beneficial Effect of Luteal-phase Gonadotropin-releasing Hormone Agonist Administration on Implantation Rate Afterintracytoplasmic Sperm Injection

Taiwanese Journal of Obstetrics and Gynecology

Volumn 48, Issue 3, 2009, Pages 245-248

  Razieh, Dehghani Firouzabadi ^a   Maryam, Ayazi Rozbahani ^a   Nasim, Tabibnejad ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

embryo implantation; GnRH agonist; intracytoplasmic sperm injection; luteal phase support

Indexed keywords

PLACEBO; TRIPTORELIN; GONADORELIN; LUTEOLYTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EMBRYO TRANSFER; FEMALE; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEAL PHASE; MAJOR CLINICAL STUDY; NIDATION; PREGNANCY RATE; SINGLE DRUG DOSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG POTENTIATION; METHODOLOGY; OVULATION INDUCTION; PHYSIOLOGY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; EMBRYO IMPLANTATION; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEAL PHASE; LUTEOLYTIC AGENTS; OVULATION INDUCTION; PLACEBOS; PREGNANCY; PREGNANCY RATE; SPERM INJECTIONS, INTRACYTOPLASMIC; TREATMENT OUTCOME; TRIPTORELIN;

EID: 73449125933     PISSN: None     EISSN: 10284559     Source Type: Journal    
DOI: 10.1016/S1028-4559(09)60297-7     Document Type: Article

References (12)

1. Macklon N.S., and Fauser B.C. Impact of ovarian hyperstimulation on the luteal phase. J Reprod Fertil Suppl 55 (2000) 101-108
2. Pritts E.A., and Atwood A.K. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 17 (2002) 2287-2299
3. Smitz J., Camus M., Devroey P., Bollen N., Tournaye H., and Van Steirteghem A.C. The influence of inadvertent intranasal buserelin administration in early pregnancy. Hum Reprod 6 (1991) 290-293
4. Al Inizi S.T., Asaad M., and Schick J. Luteal phase support in in-vitro fertilization. Middle East Fertil Soc J 11 (2006) 64-69
5. Tesarik J., Hazout A., and Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Hum Reprod 19 (2004) 1176-1180
6. Pirard C., Donnez J., and Loumaye E. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin. Hum Reprod 20 (2005) 1798-1804
7. Pirard C., Donnez J., and Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 21 (2006) 1894-1900
8. Tesarik J., Hazout A., Mendoza-Tesarik R., Mendoza N., and Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist-and antagonist-treated ovarian stimulation cycles. Hum Reprod 21 (2006) 2572-2579
9. Tavaniotou A., Albano C., Smitz J., and Devroey P. Impact of ovarian stimulation on corpus luteum function and embryonic implantation. J Reprod Immunol 55 (2002) 123-130
10. Iwashita M., Kudo Y., Shinozaki Y., and Takeda Y. Gonadotropin-releasing hormone increases serum human chorionic gonadotropin in pregnant women. Endocr J 40 (1993) 539-544
11. Lin L.S., Roberts V.J., and Yen S.S. Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion. J Clin Endocrinol Metab 80 (1995) 580-585
12. Kitajima Y., Endo T., Manase K., Nishikawa A., Shibuya M., and Kudo R. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats. Fertil Steril 81 Suppl 1 (2004) 842-849